ArticlePediatric research2026
Novel genetic variants and atypical phenotypes in pediatric progressive familial intrahepatic cholestasis.
Article in Pediatric research, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundProgressive familial intrahepatic cholestasis (PFIC) is a group of autosomal recessive disorders characterized by impaired bile formation and secretion, frequently progressing to cirrhosis and end-stage liver disease. This study characterized the genotypic and phenotypic spectrum of PFIC in a pediatric cohort.
methodsA retrospective cohort study with prospective enrollment of additional cases and longitudinal follow-up included 17 children with molecularly confirmed PFIC managed at Alexandria University Children's Hospital between 2017 and 2026. Clinical, biochemical, histopathological, genetic, therapeutic, and outcome data were reviewed.
resultsThree, ten, two, and two patients had PFIC types 1, 2, 3, and 8, respectively, with pathogenic variants in ATP8B1, ABCB11, ABCB4, and KIF12, including four novel variants. PFIC types 1 and 2 presented with early-onset low gamma-glutamyl transferase (GGT) cholestasis and severe pruritus; five patients underwent biliary diversion. PFIC type 2 showed more severe liver disease than PFIC type 1. PFIC types 3 and 8 presented later with atypical non-icteric presentations with hepatosplenomegaly and elevated GGT without classical histopathological cholestasis in three cases. Three patients underwent successful liver transplantation.
conclusionPFIC exhibits marked phenotypic heterogeneity. Recognition of atypical and non-icteric presentations broadens its clinical spectrum and highlights the importance of comprehensive genetic testing for accurate diagnosis. IMPACT STATEMENT: The study identifies and characterizes novel variants in the ABCB11, ABCB4, and KIF12 genes within an Egyptian pediatric cohort, expanding the known mutational spectrum of the disease. The study reported unusual presentation for PFIC type 3 and 8 with rapid fibrotic progression even in the absence of clinical jaundice or histological evidence of bile plugs challenging the diagnostic reliance on overt cholestasis as the primary clinical marker for PFIC.
Identifiers
42754724What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.